Pub Date : 2024-05-01DOI: 10.22159/ijpps.2024v16i5.50590
Dwipen Khanikar, Kamal Ojah, L. Borah, Mitra Bhattacharyya, Pran Pratim Saikia, Siddhartha Shankar Patowary, Diptimayee Devi
Objective: To study the demographic profile and prescription pattern in Orthopedics department in a tertiary care hospital. Methods: A prospective, observational and cross-sectional study design was adopted for this study. A total of 144 patients were enrolled and their prescriptions were analyzed for three months. The data was analyzed by using a Microsoft Excel Worksheet. The Anatomical Therapeutic Chemical classification system and defined daily dose were used to classify the prescribed drugs. Results: Out of 144 patients enrolled, 105 (72.92%) were male and 39 (27.08%) were female. Maximum patients were between 21-40 y of age. The mean age of the patients was 35.04±18.53. The average number of drugs per prescription was 4.84. Fracture of limbs (58.33%) was the most common diagnosis. Analgesics were the most commonly prescribed drugs. Diabetes was the most common comorbidity. The percentage of drugs prescribed by generic names was 48.06, and that from the essential drug list was 47.78. The percentage of fixed-dose combinations used was 28.55. Conclusion: Although we found that a good percentage of drugs were prescribed from essential drug list but, this practice has to be increased in future. It is also seen that average number of drugs per prescription was high and percentage of drugs prescribed by generic names was less than that by brand names. So, there is immense scope of improvement for prescribing in the hospital.
{"title":"EVALUATION OF PRESCRIBING PATTERN IN ORTHOPEDICS DEPARTMENT IN A TERTIARY CARE HOSPITAL: A PROSPECTIVE OBSERVATIONAL STUDY","authors":"Dwipen Khanikar, Kamal Ojah, L. Borah, Mitra Bhattacharyya, Pran Pratim Saikia, Siddhartha Shankar Patowary, Diptimayee Devi","doi":"10.22159/ijpps.2024v16i5.50590","DOIUrl":"https://doi.org/10.22159/ijpps.2024v16i5.50590","url":null,"abstract":"Objective: To study the demographic profile and prescription pattern in Orthopedics department in a tertiary care hospital.\u0000Methods: A prospective, observational and cross-sectional study design was adopted for this study. A total of 144 patients were enrolled and their prescriptions were analyzed for three months. The data was analyzed by using a Microsoft Excel Worksheet. The Anatomical Therapeutic Chemical classification system and defined daily dose were used to classify the prescribed drugs.\u0000Results: Out of 144 patients enrolled, 105 (72.92%) were male and 39 (27.08%) were female. Maximum patients were between 21-40 y of age. The mean age of the patients was 35.04±18.53. The average number of drugs per prescription was 4.84. Fracture of limbs (58.33%) was the most common diagnosis. Analgesics were the most commonly prescribed drugs. Diabetes was the most common comorbidity. The percentage of drugs prescribed by generic names was 48.06, and that from the essential drug list was 47.78. The percentage of fixed-dose combinations used was 28.55.\u0000Conclusion: Although we found that a good percentage of drugs were prescribed from essential drug list but, this practice has to be increased in future. It is also seen that average number of drugs per prescription was high and percentage of drugs prescribed by generic names was less than that by brand names. So, there is immense scope of improvement for prescribing in the hospital.","PeriodicalId":14188,"journal":{"name":"International Journal of Pharmacy and Pharmaceutical Sciences","volume":"43 18","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141030355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-01DOI: 10.22159/ijpps.2024v16i5.50574
Varshitha Srinivas, Swathy Suresh
Coronary Artery Disease (CAD) is a prevalent cardiovascular illness that is a primary cause of morbidity and mortality globally. It is distinguished by the constriction or blockage of the coronary arteries, which limits blood circulation to the heart. Inflammation is a driving force in the pathophysiology of CAD. Colchicine is an anti-inflammatory medication that has lately been studied for its potential application in the treatment of CAD. Its multimodal method of action has sparked interest due to its ability to treat inflammation and lower the concentration of critical inflammatory biomarkers. Clinical evidence validates the safe and effective use of Colchicine in CAD. Several recommendations advocate the use of colchicine in the secondary prevention of CAD. This article discusses the use of low-dose colchicine in CAD, its function in inflammation, as well as its safety and therapeutic effectiveness.
{"title":"EXPLORING THE THERAPEUTIC POTENTIAL OF LOW-DOSE COLCHICINE IN CORONARY ARTERY DISEASE: AN IN-DEPTH ANALYSIS OF INFLAMMATION, SAFETY, AND CLINICAL EFFECTIVENESS","authors":"Varshitha Srinivas, Swathy Suresh","doi":"10.22159/ijpps.2024v16i5.50574","DOIUrl":"https://doi.org/10.22159/ijpps.2024v16i5.50574","url":null,"abstract":"Coronary Artery Disease (CAD) is a prevalent cardiovascular illness that is a primary cause of morbidity and mortality globally. It is distinguished by the constriction or blockage of the coronary arteries, which limits blood circulation to the heart. Inflammation is a driving force in the pathophysiology of CAD. Colchicine is an anti-inflammatory medication that has lately been studied for its potential application in the treatment of CAD. Its multimodal method of action has sparked interest due to its ability to treat inflammation and lower the concentration of critical inflammatory biomarkers. Clinical evidence validates the safe and effective use of Colchicine in CAD. Several recommendations advocate the use of colchicine in the secondary prevention of CAD. This article discusses the use of low-dose colchicine in CAD, its function in inflammation, as well as its safety and therapeutic effectiveness.","PeriodicalId":14188,"journal":{"name":"International Journal of Pharmacy and Pharmaceutical Sciences","volume":"20 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141031157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: The present investigation aimed to prepare a smilax china loaded nanoemulsion using tween 80 as a surfactant and propylene glycol as a co-surfactant. Formulation of such drugs in nanoparticulate drug delivery will be advantageous for reducing dosing frequency, longer residence time, improved permeation, and patient compliance. Methods: High-speed homogenization method. The smilax china oil was prepared by collecting the extract of smilax china leaves into the coconut oil and then used as a solvent. The authentication studies of smilax china and coconut oil were evaluated for their organoleptic and physicochemical characteristics. The quantitative estimation and pre-formulation study of quercetin was carried out which has major anti-psoriatic properties. Surfactant and co-surfactant were selected and the solubility studies of oil and Surfactants were done. The nanoemulsion was characterized by particle size, polydispersity index, zeta potential, and entrapment efficiency (%). Results: This nanoemulsion provides the particle size and entrapment efficiency range between 80.52 to 89.78 nm and 68.66 to 70.16 % respectively. Batch SC1 showed the lowest particle size, PDI, and optimized drug entrapment effectiveness (%), indicating good particle size consistency within the remaining formulation batches. The optimized formulation SC 1 was found to be stable for 90 d. Conclusion: The formulated nanoemulsion showed significant antipsoriasis activity due to the presence of quercetin which has a rhetorical yield of 1.066 mg per 5 gm powder of smilax china leaves. Formulated smilax china-loaded nanoemulsion, has the potential as an effective antipsoriasis agent with a good spreading property with faster absorption which is beneficial for reducing drug concentration with maximum therapeutic effect.
{"title":"DESIGN AND DEVELOPMENT OF NANOEMULSION OF SMILAX CHINA FOR ANTI-PSORIASIS ACTIVITY","authors":"Vishal Bodke, Pradnya Kumbhar, Shreeya Belwalkar, Akash S. Mali, Karishma Waghmare","doi":"10.22159/ijpps.2024v16i5.50327","DOIUrl":"https://doi.org/10.22159/ijpps.2024v16i5.50327","url":null,"abstract":"Objective: The present investigation aimed to prepare a smilax china loaded nanoemulsion using tween 80 as a surfactant and propylene glycol as a co-surfactant. Formulation of such drugs in nanoparticulate drug delivery will be advantageous for reducing dosing frequency, longer residence time, improved permeation, and patient compliance.\u0000Methods: High-speed homogenization method. The smilax china oil was prepared by collecting the extract of smilax china leaves into the coconut oil and then used as a solvent. The authentication studies of smilax china and coconut oil were evaluated for their organoleptic and physicochemical characteristics. The quantitative estimation and pre-formulation study of quercetin was carried out which has major anti-psoriatic properties. Surfactant and co-surfactant were selected and the solubility studies of oil and Surfactants were done. The nanoemulsion was characterized by particle size, polydispersity index, zeta potential, and entrapment efficiency (%).\u0000Results: This nanoemulsion provides the particle size and entrapment efficiency range between 80.52 to 89.78 nm and 68.66 to 70.16 % respectively. Batch SC1 showed the lowest particle size, PDI, and optimized drug entrapment effectiveness (%), indicating good particle size consistency within the remaining formulation batches. The optimized formulation SC 1 was found to be stable for 90 d.\u0000Conclusion: The formulated nanoemulsion showed significant antipsoriasis activity due to the presence of quercetin which has a rhetorical yield of 1.066 mg per 5 gm powder of smilax china leaves. Formulated smilax china-loaded nanoemulsion, has the potential as an effective antipsoriasis agent with a good spreading property with faster absorption which is beneficial for reducing drug concentration with maximum therapeutic effect.","PeriodicalId":14188,"journal":{"name":"International Journal of Pharmacy and Pharmaceutical Sciences","volume":"90 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141034136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-01DOI: 10.22159/ijpps.2024v16i5.49167
C. A. N., Sangita Mishra, A. M., M. Venkatesh
Food and Drug Administration (FDA) has introduced a distinctive regulatory program known as Over-the-Counter Monograph Drug User Fee Program (OMUFA) to improve the efficacy and security of over-the-counter (OTC) medications made available to consumers. The program, which represents a pivotal shift in the regulatory landscape, aims to address the challenges associated with the oversight of OTC monograph drugs. The OMUFA's primary objective is to expedite the review and approval process of OTC monograph drugs while maintaining stringent safety standards. By imposing user fees on manufacturers and sponsors seeking to bring new OTC products to market or seeking updates for existing ones, the program is designed to support the FDA's ability to allocate additional resources for timely reviews and assessments. This work delves into the key components and mechanics of the OMUFA, such as the user fee structure, types of submissions covered, and the corresponding performance goals established for the FDA. While acknowledging the benefits of the OMUFA, this work also discusses potential challenges and concerns raised by industry stakeholders and consumer advocacy groups. This critical regulatory initiative has the potential to facilitate further research and discussions on optimizing drug safety and access within the OTC market through required modifications and initiatives.
美国食品和药物管理局（FDA）推出了一项名为 "非处方药专论药物用户付费计划"（OMUFA）的独特监管计划，以提高消费者可获得的非处方药（OTC）的疗效和安全性。该计划代表了监管格局的关键转变，旨在解决与监督非处方药专论药物相关的挑战。OMUFA 的主要目标是在保持严格的安全标准的同时，加快非处方药专论药物的审查和批准程序。通过向寻求将新的非处方药产品推向市场或寻求对现有产品进行更新的制造商和赞助商征收使用费，该计划旨在支持 FDA 分配更多资源用于及时审查和评估的能力。这项工作深入探讨了 OMUFA 的关键组成部分和机制，如使用费结构、涵盖的申报类型以及为 FDA 制定的相应绩效目标。在肯定 OMUFA 好处的同时，本报告还讨论了行业利益相关者和消费者权益团体提出的潜在挑战和担忧。这项重要的监管举措有可能促进进一步的研究和讨论，通过必要的修改和举措优化非处方药市场的药品安全和准入。
{"title":"ENHANCING OTC MONOGRAPH DRUG REGULATION THROUGH USER FEE PROGRAM","authors":"C. A. N., Sangita Mishra, A. M., M. Venkatesh","doi":"10.22159/ijpps.2024v16i5.49167","DOIUrl":"https://doi.org/10.22159/ijpps.2024v16i5.49167","url":null,"abstract":"Food and Drug Administration (FDA) has introduced a distinctive regulatory program known as Over-the-Counter Monograph Drug User Fee Program (OMUFA) to improve the efficacy and security of over-the-counter (OTC) medications made available to consumers. The program, which represents a pivotal shift in the regulatory landscape, aims to address the challenges associated with the oversight of OTC monograph drugs. The OMUFA's primary objective is to expedite the review and approval process of OTC monograph drugs while maintaining stringent safety standards. By imposing user fees on manufacturers and sponsors seeking to bring new OTC products to market or seeking updates for existing ones, the program is designed to support the FDA's ability to allocate additional resources for timely reviews and assessments. This work delves into the key components and mechanics of the OMUFA, such as the user fee structure, types of submissions covered, and the corresponding performance goals established for the FDA. While acknowledging the benefits of the OMUFA, this work also discusses potential challenges and concerns raised by industry stakeholders and consumer advocacy groups. This critical regulatory initiative has the potential to facilitate further research and discussions on optimizing drug safety and access within the OTC market through required modifications and initiatives.","PeriodicalId":14188,"journal":{"name":"International Journal of Pharmacy and Pharmaceutical Sciences","volume":"133 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141050257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-01DOI: 10.22159/ijpps.2024v16i5.50425
R. Manohar, P. L. Prasuna, K. A. Bajima, M. H. Reddy, S. N. VARDHAN REDDY, T. S. Babu
Objective: The objective of the study was to determine the prevalence of depression and anxiety ranges in women having Polycystic Ovarian Syndrome (PCOS). Methods: An epidemiological observational study on 80 PCOS patients confirmed through ultrasound scanning over a study period of 6 mo at Government General Hospital, RIMS, KADAPA. HAM-D and HAM-A assessment scales were used to analyze the severity of depression and anxiety in PCOS women. Results: Among 80 patients, the prevalence of depression is 86.25% (n=69) and anxiety is 93.75% (n=75). Among 69 depressed patients 38 mild, 28 moderate, and 3 severe ranges were noted. Among 75 patients with anxiety, 52 mild, 18 moderate, and 5 severe ranges were noted. The age of the patient does not show a major difference in the development of depression and anxiety. PCOS women who married and have children (n=45) were mostly affected with depression (n=39) and anxiety (n=43). Menstrual irregularity in PCOS patients with depression and anxiety is majorly seen among those who have last menstrual between 30–60 d. Middle-income patients were affected by depression and anxiety greatly, according to this study. Conclusion: We conclude that the prevalence rate of depression and anxiety is greater in PCOS patients.
{"title":"PREVALENCE OF DEPRESSION AND ANXIETY IN POLYCYSTIC OVARIAN SYNDROME WOMEN","authors":"R. Manohar, P. L. Prasuna, K. A. Bajima, M. H. Reddy, S. N. VARDHAN REDDY, T. S. Babu","doi":"10.22159/ijpps.2024v16i5.50425","DOIUrl":"https://doi.org/10.22159/ijpps.2024v16i5.50425","url":null,"abstract":"Objective: The objective of the study was to determine the prevalence of depression and anxiety ranges in women having Polycystic Ovarian Syndrome (PCOS).\u0000Methods: An epidemiological observational study on 80 PCOS patients confirmed through ultrasound scanning over a study period of 6 mo at Government General Hospital, RIMS, KADAPA. HAM-D and HAM-A assessment scales were used to analyze the severity of depression and anxiety in PCOS women.\u0000Results: Among 80 patients, the prevalence of depression is 86.25% (n=69) and anxiety is 93.75% (n=75). Among 69 depressed patients 38 mild, 28 moderate, and 3 severe ranges were noted. Among 75 patients with anxiety, 52 mild, 18 moderate, and 5 severe ranges were noted. The age of the patient does not show a major difference in the development of depression and anxiety. PCOS women who married and have children (n=45) were mostly affected with depression (n=39) and anxiety (n=43). Menstrual irregularity in PCOS patients with depression and anxiety is majorly seen among those who have last menstrual between 30–60 d. Middle-income patients were affected by depression and anxiety greatly, according to this study.\u0000Conclusion: We conclude that the prevalence rate of depression and anxiety is greater in PCOS patients.","PeriodicalId":14188,"journal":{"name":"International Journal of Pharmacy and Pharmaceutical Sciences","volume":"4 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141048306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-01DOI: 10.22159/ijpps.2024v16i5.50724
Roshni Patil, Sonal Desai
The development of bioremediation agents and processes-a sustainable solution to environmental pollution has advanced significantly. This is particularly valid when handling persistent pollutants such as Polycyclic Aromatic Hydrocarbons (PAHs). This study reviews the state-of-the-art in bioremediation technology, emphasizing the vital role that bacteria and their metabolic pathways play in the breakdown of pollutants. Microorganisms, which can be any type of fungus or bacteria, have been employed because of their unique capacity to break down a broad spectrum of contaminants. A thorough grasp of the metabolic subtleties of these bacteria is essential for optimizing bioremediation methods, especially with regard to PAH breakdown. The exploration of eco-friendly technologies, such bioaugmentation and biostimulation, emphasizes the commitment to eco-friendly approaches to environmental remediation. This review presents strong case studies and acknowledges ongoing issues to demonstrate the practical effectiveness of bioremediation. Future advancements in bioremediation-a crucial aspect of environmental management-may be possible through the combination of genetic engineering and artificial intelligence, which could assist overcome current obstacles.
{"title":"ADVANCES IN BIOREMEDIATION AGENTS AND PROCESSES FOR REMOVAL OF PERSISTENT CONTAMINANTS FROM ENVIRONMENT","authors":"Roshni Patil, Sonal Desai","doi":"10.22159/ijpps.2024v16i5.50724","DOIUrl":"https://doi.org/10.22159/ijpps.2024v16i5.50724","url":null,"abstract":"The development of bioremediation agents and processes-a sustainable solution to environmental pollution has advanced significantly. This is particularly valid when handling persistent pollutants such as Polycyclic Aromatic Hydrocarbons (PAHs). This study reviews the state-of-the-art in bioremediation technology, emphasizing the vital role that bacteria and their metabolic pathways play in the breakdown of pollutants. Microorganisms, which can be any type of fungus or bacteria, have been employed because of their unique capacity to break down a broad spectrum of contaminants. A thorough grasp of the metabolic subtleties of these bacteria is essential for optimizing bioremediation methods, especially with regard to PAH breakdown. The exploration of eco-friendly technologies, such bioaugmentation and biostimulation, emphasizes the commitment to eco-friendly approaches to environmental remediation. This review presents strong case studies and acknowledges ongoing issues to demonstrate the practical effectiveness of bioremediation. Future advancements in bioremediation-a crucial aspect of environmental management-may be possible through the combination of genetic engineering and artificial intelligence, which could assist overcome current obstacles.","PeriodicalId":14188,"journal":{"name":"International Journal of Pharmacy and Pharmaceutical Sciences","volume":"79 10","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141052513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
In recent years, there has been a rise in interest in the development of novel drug delivery systems that utilize nanoparticles. In terms of high stability, high specificity, high drug-carrying capacity, controlled release, the ability to use different routes of administration, and the ability to deliver both hydrophilic and hydrophobic drug molecules, nanoparticles can offer significant advantages over conventional drug delivery. We try to provide a detailed overview of template techniques designed for nanomaterial production. The pores and channels in the nanoporous “template” structures are used to generate the desired nanomaterials in template synthesis. Because this process has advantages over other methods, like allowing precise control over their size, shape, and structure, it is commonly used to generate nanoparticles. The first half of the review provides information on various template preparation processes. Templates are classified as “hard” or “soft” templates. Soft templates are often fluid-like, whereas hard templates are typically solid-state materials with distinct morphology and structure. This study discusses the effect of templates on morphologies and methodology and compares hard and soft templates.
{"title":"A REVIEW ON TEMPLATE SYNTHESIS OF NANOPARTICLE","authors":"Sakshi Gharat, Aishwarya Ghadge, Swapnil D. Phalak, Vishal Bodke, Aditi Gavand, Darshana Ganvir, Deepti Gaikwad","doi":"10.22159/ijpps.2024v16i5.50661","DOIUrl":"https://doi.org/10.22159/ijpps.2024v16i5.50661","url":null,"abstract":"In recent years, there has been a rise in interest in the development of novel drug delivery systems that utilize nanoparticles. In terms of high stability, high specificity, high drug-carrying capacity, controlled release, the ability to use different routes of administration, and the ability to deliver both hydrophilic and hydrophobic drug molecules, nanoparticles can offer significant advantages over conventional drug delivery. We try to provide a detailed overview of template techniques designed for nanomaterial production. The pores and channels in the nanoporous “template” structures are used to generate the desired nanomaterials in template synthesis. Because this process has advantages over other methods, like allowing precise control over their size, shape, and structure, it is commonly used to generate nanoparticles. The first half of the review provides information on various template preparation processes. Templates are classified as “hard” or “soft” templates. Soft templates are often fluid-like, whereas hard templates are typically solid-state materials with distinct morphology and structure. This study discusses the effect of templates on morphologies and methodology and compares hard and soft templates.","PeriodicalId":14188,"journal":{"name":"International Journal of Pharmacy and Pharmaceutical Sciences","volume":"28 9","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141041647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-01DOI: 10.22159/ijpps.2024v16i5.49277
K. R. K., Sangita Mishra, A. M., M. Venkatesh
The audit process is a crucial component of regulatory compliance and quality assurance in both the United States of America (USA) and the European Union (EU). This review paper compares and analyses the audit processes, results, and ramifications in these two important markets. The study investigates how pharmaceutical audits affect patients’ trust, market stability, and profitability of a company while highlighting the need for adherence to quality standards. Data integrity, supply chain complexity, and adherence to exacting quality standards are just a few of the notable difficulties faced by auditors in the USA and EU. There is a need to have a strong pharmacovigilance system as well to guarantee the security and effectiveness of pharmaceutical products for patients. This study can be useful reference material for stakeholders, decision-makers, and companies looking to increase accountability, reduce risks, and uphold the integrity of a firm’s operations in the global market. A thorough analysis of audit procedures in the USA and EU will facilitate in promotion of effective and efficient manufacturing, control, and distribution of pharmaceutical products while boosting confidence among patients and in the healthcare system as a whole.
{"title":"PHARMACEUTICAL AUDIT PROCESS, OUTCOMES, AND IMPLICATIONS–OVERVIEW","authors":"K. R. K., Sangita Mishra, A. M., M. Venkatesh","doi":"10.22159/ijpps.2024v16i5.49277","DOIUrl":"https://doi.org/10.22159/ijpps.2024v16i5.49277","url":null,"abstract":"The audit process is a crucial component of regulatory compliance and quality assurance in both the United States of America (USA) and the European Union (EU). This review paper compares and analyses the audit processes, results, and ramifications in these two important markets.\u0000The study investigates how pharmaceutical audits affect patients’ trust, market stability, and profitability of a company while highlighting the need for adherence to quality standards. Data integrity, supply chain complexity, and adherence to exacting quality standards are just a few of the notable difficulties faced by auditors in the USA and EU. There is a need to have a strong pharmacovigilance system as well to guarantee the security and effectiveness of pharmaceutical products for patients.\u0000This study can be useful reference material for stakeholders, decision-makers, and companies looking to increase accountability, reduce risks, and uphold the integrity of a firm’s operations in the global market. A thorough analysis of audit procedures in the USA and EU will facilitate in promotion of effective and efficient manufacturing, control, and distribution of pharmaceutical products while boosting confidence among patients and in the healthcare system as a whole.","PeriodicalId":14188,"journal":{"name":"International Journal of Pharmacy and Pharmaceutical Sciences","volume":"27 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141055033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-01DOI: 10.22159/ijpps.2024v16i5.50845
Chitra Selvarajan, Nalini Ganesan
Rheumatoid Arthritis (RA) is a common autoimmune disease that causes chronic inflammation of the tissues around the joints, which eventually results in systemic complications and bone destruction. Macrophages are critical cells in many tissues and organs essential to an innate and adaptive immune response. It is one of the most common cell types in the synovium of rheumatoid arthritis. Various conventional and experimental therapies for RA target proteins, cytokines or their synthetic pathways, T lymphocytes, and B lymphocytes. The Fibroblast-Like Synoviocytes (FLS) and macrophages are abundantly activated in RA, and the drugs targeting the monocytes and macrophages are explored significantly less. The drugs targeting monocytes and macrophages may provide a better therapeutic strategy for RA. Proteasome inhibitors act as a potential remedy for autoimmune and inflammatory diseases. Targeting the monocytes and macrophages with proteasome inhibitors may improve the therapeutic approaches to RA. This paper reviews the types and significance of macrophages in RA, various conventional and experimental therapy approaches targeting monocytes and macrophages, and the effect of proteasome inhibitors on macrophages in RA.
类风湿性关节炎（RA）是一种常见的自身免疫性疾病，会引起关节周围组织的慢性炎症，最终导致全身并发症和骨质破坏。巨噬细胞是许多组织和器官中的关键细胞，对先天性和适应性免疫反应至关重要。它是类风湿性关节炎滑膜中最常见的细胞类型之一。 针对类风湿性关节炎的各种传统和实验疗法都以蛋白质、细胞因子或其合成途径、T 淋巴细胞和 B 淋巴细胞为靶点。纤维母细胞样滑膜细胞（FLS）和巨噬细胞在 RA 中大量活化，而针对单核细胞和巨噬细胞的药物却鲜有研究。针对单核细胞和巨噬细胞的药物可能为 RA 提供更好的治疗策略。蛋白酶体抑制剂是治疗自身免疫性和炎症性疾病的潜在药物。以单核细胞和巨噬细胞为靶点的蛋白酶体抑制剂可能会改善RA的治疗方法。本文综述了RA中巨噬细胞的类型和意义、针对单核细胞和巨噬细胞的各种常规和实验治疗方法，以及蛋白酶体抑制剂对RA中巨噬细胞的影响。
{"title":"A REVIEW ON MACROPHAGES AND THE IMPACT OF PROTEASOME INHIBITORS ON RHEUMATOID ARTHRITIS","authors":"Chitra Selvarajan, Nalini Ganesan","doi":"10.22159/ijpps.2024v16i5.50845","DOIUrl":"https://doi.org/10.22159/ijpps.2024v16i5.50845","url":null,"abstract":"Rheumatoid Arthritis (RA) is a common autoimmune disease that causes chronic inflammation of the tissues around the joints, which eventually results in systemic complications and bone destruction. Macrophages are critical cells in many tissues and organs essential to an innate and adaptive immune response. It is one of the most common cell types in the synovium of rheumatoid arthritis. Various conventional and experimental therapies for RA target proteins, cytokines or their synthetic pathways, T lymphocytes, and B lymphocytes. The Fibroblast-Like Synoviocytes (FLS) and macrophages are abundantly activated in RA, and the drugs targeting the monocytes and macrophages are explored significantly less. The drugs targeting monocytes and macrophages may provide a better therapeutic strategy for RA. Proteasome inhibitors act as a potential remedy for autoimmune and inflammatory diseases. Targeting the monocytes and macrophages with proteasome inhibitors may improve the therapeutic approaches to RA. This paper reviews the types and significance of macrophages in RA, various conventional and experimental therapy approaches targeting monocytes and macrophages, and the effect of proteasome inhibitors on macrophages in RA.","PeriodicalId":14188,"journal":{"name":"International Journal of Pharmacy and Pharmaceutical Sciences","volume":"3 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141047012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-01DOI: 10.22159/ijpps.2024v16i4.50277
D. R. Prakash, C. S. Kumar, Satya Narayana, Deepak
Objective: Various treatment options are available for knee osteoarthritis such as medical treatment with NSAID, conservative management with platelet-rich plasma (PRP) and corticosteroids. We have done this prospective study to know the use and safety of platelet- rich plasma (PRP) injections in knee osteoarthritis (KOA) patients. We know platelet rich plasma (PRP) clinical and functional outcome in knee osteoarthritis (KOA) by doing this study and using the available literature. Methods: This prospective study consisted of a total number of 96 patients suffering from knee osteoarthritis. Both males and females are included. Intra-articular injection of platelet rich plasma (PRP) was given in sterile conditions and clinical and functional outcomes were analyzed with Western Ontario and McMaster University Arthritis Index (WOMAC), Visual Analogic Scale (VAS), and Knee Society score (KSS). This study is done in a tertiary care institute during the study period.Results: Most patients were females aged>40 years with knee osteoarthritis. The injections of platelet rich plasma (PRP) showed results at three, six and twelve months follow-up showed significantly reduced WOMAC scores, Visual Analogic Scale (VAS) and Knee Society score (KSS). No complications were observed during the follow-up period. Conclusion: The results confirm the efficacy of the PRP injections on Knee osteoarthritis, suggesting that decreasing pain was obtained one month after injection, with the best results observed after 12 months—however, a more extensive study group. Follow-up is required for a prolonged period to assess the efficacy of PRP injection.
{"title":"EFFECTS OF PLATELET-RICH PLASMA INJECTIONS ON OSTEOARTHRITIC PATIENTS","authors":"D. R. Prakash, C. S. Kumar, Satya Narayana, Deepak","doi":"10.22159/ijpps.2024v16i4.50277","DOIUrl":"https://doi.org/10.22159/ijpps.2024v16i4.50277","url":null,"abstract":"Objective: Various treatment options are available for knee osteoarthritis such as medical treatment with NSAID, conservative management with platelet-rich plasma (PRP) and corticosteroids. We have done this prospective study to know the use and safety of platelet- rich plasma (PRP) injections in knee osteoarthritis (KOA) patients. We know platelet rich plasma (PRP) clinical and functional outcome in knee osteoarthritis (KOA) by doing this study and using the available literature.\u0000Methods: This prospective study consisted of a total number of 96 patients suffering from knee osteoarthritis. Both males and females are included. Intra-articular injection of platelet rich plasma (PRP) was given in sterile conditions and clinical and functional outcomes were analyzed with Western Ontario and McMaster University Arthritis Index (WOMAC), Visual Analogic Scale (VAS), and Knee Society score (KSS). This study is done in a tertiary care institute during the study period.Results: Most patients were females aged>40 years with knee osteoarthritis. The injections of platelet rich plasma (PRP) showed results at three, six and twelve months follow-up showed significantly reduced WOMAC scores, Visual Analogic Scale (VAS) and Knee Society score (KSS). No complications were observed during the follow-up period.\u0000Conclusion: The results confirm the efficacy of the PRP injections on Knee osteoarthritis, suggesting that decreasing pain was obtained one month after injection, with the best results observed after 12 months—however, a more extensive study group. Follow-up is required for a prolonged period to assess the efficacy of PRP injection.","PeriodicalId":14188,"journal":{"name":"International Journal of Pharmacy and Pharmaceutical Sciences","volume":"45 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140762857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：